Get the Stockscreener App
7.7045
2.15%
-0.2155
Zevra Therapeutics Inc stock is traded at $7.7045, with a volume of 220.46K.
It is down -2.15% in the last 24 hours and down -3.00% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$7.92
Open:
$7.84
24h Volume:
220.46K
Relative Volume:
0.52
Market Cap:
$427.54M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-5.9725
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-3.73%
1M Performance:
-3.00%
6M Performance:
-1.27%
1Y Performance:
+23.41%
1-Day Range:
$7.68
$8.29
1-Week Range:
$7.32
$8.2999
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.68 | 427.54M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.30 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.83 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.49 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.97 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com South Africa
Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com
Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa
Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com
Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks
Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Zevra Therapeutics: Q4 Earnings Snapshot - mySA
ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses - Investing.com
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com UK
Zevra Therapeutics: Q4 Earnings Snapshot -March 11, 2025 at 05:23 pm EDT - Marketscreener.com
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours - Marketscreener.com
Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewswire
Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction - StockTitan
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects - Simply Wall St
Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday - Defense World
Rhumbline Advisers Has $568,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra at TD Cowen Conference: Strategic Shifts in Rare Disease Focus - Investing.com
(ZVRA) Long Term Investment Analysis - Stock Traders Daily
Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain - Yahoo Finance
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - The Globe and Mail
Watkins Represents Zevra Therapeutics in Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher - Latham & Watkins LLP
Zevra Seals PRV Sale And Banks $150m - Citeline News & Insights
Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating - TipRanks
Zevra Launches New Disease State Awareness Campaign, ‘Learn - GlobeNewswire
Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - The Manila Times
Zevra sells priority review voucher for $150m to support drug launches - Pharmaceutical Technology
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M - MedCity News
Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln - TradingView
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million - The Pharma Letter
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million -February 27, 2025 at 11:12 am EST - Marketscreener.com
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million - MarketWatch
Zevra Therapeutics Sells Priority Review Voucher for $150M - TipRanks
Zevra Therapeutics stock rises on $150M asset sale By Investing.com - Investing.com Canada
Zevra Therapeutics stock rises on $150M asset sale - Investing.com
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - Benzinga
How Will Zevra Use Its Massive $150M Windfall? Non-Dilutive Funding Fuels Rare Disease Strategy - StockTitan
ZEVRA THERAPEUTICS Earnings Preview: Recent $ZVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results - The Manila Times
When Will Zevra Reveal Its 2024 Financial Performance? Key Date for Rare Disease Investors - StockTitan
Zevra to Participate at Upcoming Investor Conferences - The Manila Times
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schafer Joshua | CCO & EVP, Bus. Development |
Feb 13 '25 |
Sale |
7.86 |
10,500 |
82,527 |
29,486 |
| Clifton R. LaDuane | CFO & Treasurer |
Feb 13 '25 |
Sale |
7.86 |
11,000 |
86,471 |
51,361 |
| McFarlane Neil F. | President and CEO |
Feb 13 '25 |
Sale |
7.86 |
61,273 |
481,428 |
222,060 |
| McFarlane Neil F. | President and CEO |
Feb 14 '25 |
Sale |
8.05 |
30,544 |
245,962 |
191,516 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):